Literature DB >> 31390552

Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1α expression.

Wenhe Zhu1, Yawei Li1, Donghai Zhao1, Huilin Li1, Wei Zhang1, Junjie Xu1, Jiancheng Hou1, Xianmin Feng1, Huiyan Wang2.   

Abstract

AIMS: Dihydroartemisinin (DHA) exhibits potential anticancer activity. However, the biological functions of DHA in prostate cancer remain largely unexplored. In this study, we aim to investigate the anti-proliferative effect and glycolysis regulation of DHA on prostate cancer cell LNCaP. MAIN
METHODS: Cell proliferative activity and apoptosis inducing were detected. The gene expression was detected by mRNA microarray and results were analyzed by GO and KEGG pathway database. Expressions of glycolysis key enzymes and PI3K/AKT/HIF-1α were detected by Western blot. KEY
FINDINGS: Results indicated that DHA could inhibit the LNCaP cell proliferation considerably and induce cell apoptosis. mRNA microarray showed 1293 genes were upregulated and 2322 genes were downregulated. GO and KEGG enrichment analysis suggested that glycolysis pathway was correlated with DHA inhibited the proliferation on the LNCaP cell. Western blot results showed that DHA can decrease GLUT1 and regulatory enzymes of glycolytic pathway expression probably by suppressing the activity of the intracellular Akt/mTOR and HIF-1 α. SIGNIFICANCE: Experimental validation results indicate that DHA treatment can inhibit the LNCaP cell proliferation and induce apoptosis, which may be related to glycolysis inhibition.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt/mTOR; Dihydroartemisinin; Glycolysis; HIF-1 α; Prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31390552     DOI: 10.1016/j.lfs.2019.116730

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.

Authors:  Qing Peng; Liyuan Hao; Yinglin Guo; Zhiqin Zhang; Jingmin Ji; Yu Xue; Yiwei Liu; Caige Li; Junlan Lu; Xinli Shi
Journal:  J Nat Med       Date:  2022-09-06       Impact factor: 3.192

2.  Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells.

Authors:  Yuanshen Mao; Wenfeng Li; Bao Hua; Xin Gu; Weixin Pan; Qi Chen; Bin Xu; Zhong Wang; Chao Lu
Journal:  Biomed Res Int       Date:  2020-02-13       Impact factor: 3.411

Review 3.  Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches.

Authors:  Carla Navarro; Ángel Ortega; Raquel Santeliz; Bermary Garrido; Maricarmen Chacín; Néstor Galban; Ivana Vera; Juan Bautista De Sanctis; Valmore Bermúdez
Journal:  Pharmaceutics       Date:  2022-06-19       Impact factor: 6.525

Review 4.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162

5.  Dihydroartemisinin Inhibits mTORC1 Signaling by Activating the AMPK Pathway in Rhabdomyosarcoma Tumor Cells.

Authors:  Jun Luo; Yoshinobu Odaka; Zhu Huang; Bing Cheng; Wang Liu; Lin Li; Chaowei Shang; Chao Zhang; Yang Wu; Yan Luo; Shengyong Yang; Peter J Houghton; Xiaofeng Guo; Shile Huang
Journal:  Cells       Date:  2021-06-01       Impact factor: 7.666

Review 6.  PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.

Authors:  Rui Liu; Youwen Chen; Guangzhi Liu; Chenxi Li; Yurong Song; Zhiwen Cao; Wen Li; Jinghong Hu; Cheng Lu; Yuanyan Liu
Journal:  Cell Death Dis       Date:  2020-09-24       Impact factor: 8.469

Review 7.  Dihydroartemisinin: A Potential Natural Anticancer Drug.

Authors:  Xiaoshuo Dai; Xiaoyan Zhang; Wei Chen; Yihuan Chen; Qiushuang Zhang; Saijun Mo; Jing Lu
Journal:  Int J Biol Sci       Date:  2021-01-16       Impact factor: 6.580

Review 8.  Recent Advances in the Therapeutic Efficacy of Artesunate.

Authors:  Ngonidzashe Ruwizhi; Rejoice Bethusile Maseko; Blessing Atim Aderibigbe
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.